年龄对全球ICU临终治疗限制实践的影响(ETHICUS-2):一项前瞻性观察研究
该多国、多中心、前瞻性观察研究纳入36个国家199个ICU在2015年9月至2016年9月6个月期间连续收治的死亡和/或接受生命维持治疗限制(不启动、撤除或主动缩短临终过程)的成年患者,共12,200例。按年龄分为65岁以下、65-79岁和80岁及以上三组。多因素logistic回归显示,80岁及以上组接受任何生命维持治疗限制的OR为1.47(95%CI 1.22-1.76,p<0.001),高于65岁以下组;按地区分层,该关联在中欧和南欧显著(OR 1.56 [95%CI 1.11-2.20],p=0.037;OR 2.23 [95%CI 1.58-3.17],p<0.001),其他地区不显著。80岁及以上组不启动治疗的比例最高,而65岁以下组撤除治疗的比例最高;80岁及以上组从ICU入住到首次限制的时间更短。所有年龄组限制的主要原因是最大治疗无反应,其次是神经系统疾病和慢性疾病;年龄很少是限制的主要原因。
要点
- 80岁及以上患者接受任何生命维持治疗限制的OR为1.47(95%CI 1.22-1.76,p<0.001),高于65岁以下患者。
- 按地区分层,该关联仅在中欧(OR 1.56 [95%CI 1.11-2.20],p=0.037)和南欧(OR 2.23 [95%CI 1.58-3.17],p<0.001)显著,其他地区不显著。
- 80岁及以上组不启动治疗的比例最高,65岁以下组撤除治疗的比例最高。
- 80岁及以上组从ICU入住到首次限制的时间更短。
- 所有年龄组限制的主要原因是最大治疗无反应,其次是神经系统疾病和慢性疾病;年龄很少是限制的主要原因。
适用人群与场景
- 36个国家199个ICU在2015年9月至2016年9月6个月期间连续收治的死亡和/或接受生命维持治疗限制(不启动、撤除或主动缩短临终过程)的成年患者,共12,200例。
- 按年龄分为65岁以下、65-79岁和80岁及以上三组。
研究设计与关键结果
- 多国、多中心、前瞻性观察研究,纳入36个国家199个ICU的12,200例成年患者。
- 多因素logistic回归显示,80岁及以上组接受任何生命维持治疗限制的OR为1.47(95%CI 1.22-1.76,p<0.001),高于65岁以下组。
- 按地区分层,中欧OR为1.56(95%CI 1.11-2.20,p=0.037),南欧OR为2.23(95%CI 1.58-3.17,p<0.001),其他地区不显著。
- 80岁及以上组不启动治疗的比例最高,65岁以下组撤除治疗的比例最高。
- 80岁及以上组从ICU入住到首次限制的时间更短。
- 所有年龄组限制的主要原因是最大治疗无反应,其次是神经系统疾病和慢性疾病;年龄很少是限制的主要原因。
证据类型、等级与局限
- 证据类型:多国、多中心、前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究提示,80岁及以上患者接受生命维持治疗限制的 odds 高于65岁以下患者,且存在地区差异;年龄很少是限制的主要原因,限制的主要原因是最大治疗无反应、神经系统疾病和慢性疾病。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The practice of limiting life-sustaining therapy (LST) at end-of-life is widespread globally. The goal of this study was to evaluate whether patient's age influences end-of-life limitations overall and of various LST in ICUs worldwide.
DESIGN: Multinational, multicenter, prospective observational study.
SETTING: One hundred ninety-nine ICUs in 36 countries worldwide.
PATIENTS: Consecutive adult patients admitted to ICUs who died and/or had LST limitations (withholding, withdrawing, or active shortening of the dying process) were included during a 6-month period between September 2015 and September 2016.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Patients were grouped: younger than 65 years, 65-79 years old, and 80 years old or older. A total of 12,200 patients were included. In multivariate logistic regression analysis, odds ratio (OR) for any LST limitation in the 80 years old or older group was higher than in younger than the 65 years old group (OR 1.47 [95% CI, 1.22-1.76], p < 0.001). When stratified by region, this association was significant in Central and Southern Europe (OR 1.56 [95% CI, 1.11-2.20], p = 0.037 and OR 2.23 [95% CI, 1.58-3.17], p < 0.001, respectively), but not in the other regions. The proportion of withholding therapy of each LST was highest in the group of individuals 80 years or older, whereas the proportion of withdrawing therapy was highest in the group younger than 65 years. The 80-year-old or older group also had a shorter time from ICU admission to first limitation. The predominant reason for any LST limitation in all age groups was unresponsiveness to maximal therapy, followed by neurologic and chronic diseases. Patient age was rarely the primary reason for limitations for all groups.
CONCLUSIONS: End-of-life limitations were higher in patients 80 years or older compared to those 65 years old or younger, with regional variations. The main reasons for limitations were comparable across age groups, with age not being the primary reason.
参考来源
- Nagata I, Sprung CL, Lautrette A, et al. Influence of Age in End-of-Life Practices in Worldwide ICUs (ETHICUS-2): A Prospective Observational Study. Crit Care Med. 2026. PMID: 41860289. doi:10.1097/CCM.0000000000007091
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。